{"podcast":{"title":"Few & Far Between: How Biotech Gets Built","slug":"few-far-between-how-biotech-gets-built-4067896","podcast_index_feed_id":4067896,"rss_url":"https://feeds.castos.com/kd1o1","website_url":"https://biorasi.com/few-far-between-podcast/","image_url":"https://episodes.castos.com/6026d270a471b8-76273800/images/podcast/covers/c1a-7krkv-5zqr8dopfxo9-ndltai.jpg","author":"Adam Gottlieb","episode_count":35,"summary":"Welcome to Few & Far Between! Melissa Alesse, President of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.","last_synced_at":null,"page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896"},"episodes":[{"title":"Episode 71: Chris O'Brien, Former ⁨Biorasi⁩ CEO and Current CEO of ⁨Rancho Biosciences","slug":"episode-71-chris-o-brien-former-biorasi-ceo-and-current-ceo-of-rancho-biosciences","published_at":"2026-05-12T12:08:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-71-chris-o-brien-former-biorasi-ceo-and-current-ceo-of-rancho-biosciences","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/x-episode","duration_seconds":2604,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-71-chris-o-brien-former-biorasi-ceo-and-current-ceo-of-rancho-biosciences/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-71-chris-o-brien-former-biorasi-ceo-and-current-ceo-of-rancho-biosciences.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 69: Zak Kohane, Chair of the Department of Biomedical Informatics at Harvard Medical School","slug":"episode-69-zak-kohane-chair-of-the-department-of-biomedical-informatics-at-harvard-medical-school","published_at":"2026-03-17T10:04:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-69-zak-kohane-chair-of-the-department-of-biomedical-informatics-at-harvard-medical-school","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-69","duration_seconds":3746,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-69-zak-kohane-chair-of-the-department-of-biomedical-informatics-at-harvard-medical-school/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-69-zak-kohane-chair-of-the-department-of-biomedical-informatics-at-harvard-medical-school.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Video Episode 68: Sinan Gölhan, CEO at GelTech Labs","slug":"video-episode-68-sinan-g-lhan-ceo-at-geltech-labs","published_at":"2026-01-27T10:30:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/video-episode-68-sinan-g-lhan-ceo-at-geltech-labs","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/sinan","duration_seconds":2656,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/video-episode-68-sinan-g-lhan-ceo-at-geltech-labs/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/video-episode-68-sinan-g-lhan-ceo-at-geltech-labs.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Video Episode 67: Aoife Brennan, President and CEO of Climb Bio","slug":"video-episode-67-aoife-brennan-president-and-ceo-of-climb-bio","published_at":"2026-01-07T10:28:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/video-episode-67-aoife-brennan-president-and-ceo-of-climb-bio","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/video-episode-67","duration_seconds":4319,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/video-episode-67-aoife-brennan-president-and-ceo-of-climb-bio/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/video-episode-67-aoife-brennan-president-and-ceo-of-climb-bio.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 66: Mark Abelson, Founder of Ora Clinical","slug":"episode-66-mark-abelson-founder-of-ora-clinical","published_at":"2025-12-16T10:20:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-66-mark-abelson-founder-of-ora-clinical","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-66-mark-abelson-founder-of-ora-clinical","duration_seconds":2607,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-66-mark-abelson-founder-of-ora-clinical/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-66-mark-abelson-founder-of-ora-clinical.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Video Episode 65 - Amit Etkin, Founder and CEO of Alto Neuroscience","slug":"video-episode-65-amit-etkin-founder-and-ceo-of-alto-neuroscience","published_at":"2025-11-24T16:06:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/video-episode-65-amit-etkin-founder-and-ceo-of-alto-neuroscience","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-65","duration_seconds":4011,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/video-episode-65-amit-etkin-founder-and-ceo-of-alto-neuroscience/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/video-episode-65-amit-etkin-founder-and-ceo-of-alto-neuroscience.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Video Episode 64 - Professor Justin Stebbing","slug":"video-episode-64-professor-justin-stebbing","published_at":"2025-11-11T10:29:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/video-episode-64-professor-justin-stebbing","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-64-professor-justin-stebbing","duration_seconds":2850,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/video-episode-64-professor-justin-stebbing/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/video-episode-64-professor-justin-stebbing.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Video Episode 63 - Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences","slug":"video-episode-63-bruce-leuchter-md-president-and-ceo-of-neurvati-neurosciences","published_at":"2025-10-28T09:54:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/video-episode-63-bruce-leuchter-md-president-and-ceo-of-neurvati-neurosciences","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/video-episode-63-bruce-leuchter-md-president-and-ceo-of-neurvati-neurosciences","duration_seconds":3676,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/video-episode-63-bruce-leuchter-md-president-and-ceo-of-neurvati-neurosciences/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/video-episode-63-bruce-leuchter-md-president-and-ceo-of-neurvati-neurosciences.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 62: Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology","slug":"episode-62-ken-suzuki-chief-marketing-officer-at-nautilus-biotechnology","published_at":"2025-10-22T09:53:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-62-ken-suzuki-chief-marketing-officer-at-nautilus-biotechnology","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-62-ken-suzuki-chief-marketing-officer-at-nautilus-biotechnology","duration_seconds":2655,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-62-ken-suzuki-chief-marketing-officer-at-nautilus-biotechnology/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-62-ken-suzuki-chief-marketing-officer-at-nautilus-biotechnology.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 61: Woody Bryan, President and CEO of Revolo Biotherapeutics","slug":"episode-61-woody-bryan-president-and-ceo-of-revolo-biotherapeutics","published_at":"2025-10-01T09:32:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-61-woody-bryan-president-and-ceo-of-revolo-biotherapeutics","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-61-woody-bryan-president-and-ceo-of-revolo-biotherapeutics","duration_seconds":2718,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-61-woody-bryan-president-and-ceo-of-revolo-biotherapeutics/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-61-woody-bryan-president-and-ceo-of-revolo-biotherapeutics.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 60: Part Two: Yochi Slonim, Co-Founder and CEO at Anima Biotech","slug":"episode-60-part-two-yochi-slonim-co-founder-and-ceo-at-anima-biotech","published_at":"2025-09-17T09:22:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-60-part-two-yochi-slonim-co-founder-and-ceo-at-anima-biotech","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-60-part-two-yochi-slonim-co-founder-and-ceo-at-anima-biotech","duration_seconds":2531,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-60-part-two-yochi-slonim-co-founder-and-ceo-at-anima-biotech/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-60-part-two-yochi-slonim-co-founder-and-ceo-at-anima-biotech.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 59, Part One: Yochi Slonim, Co-Founder and CEO at Anima Biotech","slug":"episode-59-part-one-yochi-slonim-co-founder-and-ceo-at-anima-biotech","published_at":"2025-09-03T10:39:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-59-part-one-yochi-slonim-co-founder-and-ceo-at-anima-biotech","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-59-part-one-yochi-slonim-co-founder-and-ceo-at-anima-biotech","duration_seconds":2621,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-59-part-one-yochi-slonim-co-founder-and-ceo-at-anima-biotech/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-59-part-one-yochi-slonim-co-founder-and-ceo-at-anima-biotech.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 58: Jerry McLaughlin, CEO and Board Member at Life Biosciences","slug":"episode-58-jerry-mclaughlin-ceo-and-board-member-at-life-biosciences","published_at":"2025-08-14T09:25:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-58-jerry-mclaughlin-ceo-and-board-member-at-life-biosciences","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-58-jerry-mclaughlin-ceo-and-board-member-at-life-biosciences","duration_seconds":2683,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-58-jerry-mclaughlin-ceo-and-board-member-at-life-biosciences/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-58-jerry-mclaughlin-ceo-and-board-member-at-life-biosciences.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 57: Jim Brown, DVM, President and CEO of DURECT Corporation","slug":"episode-57-jim-brown-dvm-president-and-ceo-of-durect-corporation","published_at":"2025-07-22T09:19:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-57-jim-brown-dvm-president-and-ceo-of-durect-corporation","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-57-jim-brown-dvm-president-and-ceo-of-durmuy","duration_seconds":2693,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-57-jim-brown-dvm-president-and-ceo-of-durect-corporation/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-57-jim-brown-dvm-president-and-ceo-of-durect-corporation.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 56, Part Two: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics","slug":"episode-56-part-two-michael-tolentino-md-co-founder-and-head-scientific-consultant-aviceda-therapeutics","published_at":"2025-07-15T09:28:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-56-part-two-michael-tolentino-md-co-founder-and-head-scientific-consultant-aviceda-therapeutics","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-56-part-two-michael-tolentino-md-co-foun3dj","duration_seconds":2368,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-56-part-two-michael-tolentino-md-co-founder-and-head-scientific-consultant-aviceda-therapeutics/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-56-part-two-michael-tolentino-md-co-founder-and-head-scientific-consultant-aviceda-therapeutics.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 55: Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®","slug":"episode-55-julio-g-martinez-clark-ceo-and-co-founder-at-bioaccess","published_at":"2025-07-09T09:23:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-55-julio-g-martinez-clark-ceo-and-co-founder-at-bioaccess","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-56-julio-g-martinez-clark-ceo-and-co-founxst","duration_seconds":2326,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-55-julio-g-martinez-clark-ceo-and-co-founder-at-bioaccess/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-55-julio-g-martinez-clark-ceo-and-co-founder-at-bioaccess.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 54, Part One: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics","slug":"episode-54-part-one-michael-tolentino-md-co-founder-and-head-scientific-consultant-aviceda-therapeutics","published_at":"2025-05-28T09:13:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-54-part-one-michael-tolentino-md-co-founder-and-head-scientific-consultant-aviceda-therapeutics","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-54-part-one-michael-tolentino-md-co-founder-and-head-scientific-consultant-aviceda-therapeutics","duration_seconds":2711,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-54-part-one-michael-tolentino-md-co-founder-and-head-scientific-consultant-aviceda-therapeutics/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-54-part-one-michael-tolentino-md-co-founder-and-head-scientific-consultant-aviceda-therapeutics.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 53: Frank David, Founder and Managing Director, Pharmagellan","slug":"episode-53-frank-david-founder-and-managing-director-pharmagellan","published_at":"2025-04-29T10:35:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-53-frank-david-founder-and-managing-director-pharmagellan","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-53-frank-david-founder-and-managing-director-pharmagellan","duration_seconds":3046,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-53-frank-david-founder-and-managing-director-pharmagellan/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-53-frank-david-founder-and-managing-director-pharmagellan.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 52: Joshua Kresh, Emily Michiko Morris, and Mark Schultz, IPPI","slug":"episode-52-joshua-kresh-emily-michiko-morris-and-mark-schultz-ippi","published_at":"2025-04-23T09:47:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-52-joshua-kresh-emily-michiko-morris-and-mark-schultz-ippi","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-52-joshua-kresh-emily-michiko-morris-and-mark-schultz-ippi","duration_seconds":3125,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-52-joshua-kresh-emily-michiko-morris-and-mark-schultz-ippi/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-52-joshua-kresh-emily-michiko-morris-and-mark-schultz-ippi.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 51: Dan Oliver, CEO and Founder, Rejuvenate Bio","slug":"episode-51-dan-oliver-ceo-and-founder-rejuvenate-bio","published_at":"2025-04-03T09:18:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-51-dan-oliver-ceo-and-founder-rejuvenate-bio","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-51-dan-oliver-ceo-and-founder-rejuvenate-bio","duration_seconds":3305,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-51-dan-oliver-ceo-and-founder-rejuvenate-bio/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-51-dan-oliver-ceo-and-founder-rejuvenate-bio.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Epsiode 50: Jonathan Rigby, Chairman and CEO, Sernova","slug":"epsiode-50-jonathan-rigby-chairman-and-ceo-sernova","published_at":"2025-03-18T09:09:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/epsiode-50-jonathan-rigby-chairman-and-ceo-sernova","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/epsiode-50-jonathan-rigby-chairman-and-ceo-sernova","duration_seconds":3122,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/epsiode-50-jonathan-rigby-chairman-and-ceo-sernova/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/epsiode-50-jonathan-rigby-chairman-and-ceo-sernova.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 49: Eileen Faucher, Principal and Founder, Brass Tacks Health","slug":"episode-49-eileen-faucher-principal-and-founder-brass-tacks-health","published_at":"2025-02-27T10:13:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-49-eileen-faucher-principal-and-founder-brass-tacks-health","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-49-eileen-faucher-principal-and-founder-brass-tacks-health","duration_seconds":2137,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-49-eileen-faucher-principal-and-founder-brass-tacks-health/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-49-eileen-faucher-principal-and-founder-brass-tacks-health.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 48: John Celebi, President and CEO, Sensei Bio","slug":"episode-48-john-celebi-president-and-ceo-sensei-bio","published_at":"2025-02-18T10:08:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-48-john-celebi-president-and-ceo-sensei-bio","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-48-john-celebi-president-and-ceo-sensei-bio","duration_seconds":2326,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-48-john-celebi-president-and-ceo-sensei-bio/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-48-john-celebi-president-and-ceo-sensei-bio.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 46: Ben Olds and Amy Fenollosa, Haven Human Asset Ventures","slug":"episode-46-ben-olds-and-amy-fenollosa-haven-human-asset-ventures","published_at":"2025-01-15T12:06:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-46-ben-olds-and-amy-fenollosa-haven-human-asset-ventures","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-46-ben-olds-and-amy-fenollosa-haven-human-asset-ventures","duration_seconds":2609,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-46-ben-olds-and-amy-fenollosa-haven-human-asset-ventures/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-46-ben-olds-and-amy-fenollosa-haven-human-asset-ventures.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Episode 47 - Marc Lajoie, CEO at Outpace Bio","slug":"episode-47-marc-lajoie-ceo-at-outpace-bio","published_at":"2024-12-31T10:11:00+00:00","page_url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-47-marc-lajoie-ceo-at-outpace-bio","url":"https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-47-marc-lajoie-ceo-at-outpace-bio","duration_seconds":2905,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-47-marc-lajoie-ceo-at-outpace-bio/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-47-marc-lajoie-ceo-at-outpace-bio.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}]}